Transcription of BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY …
{{id}} {{{paragraph}}}
Example: bankruptcy
BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY …
BC CANCER CHEMOTHERAPY PREPARATION and STABILITY Chart version 1/49 Activation Date: 2 March 2006 Revised Date: 15 August 2018 BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status) Reconstitute With: To Give: Vial STABILITY product product STABILITY Special Precautions/Notes Aldesleukin 22 million units ( mg) (Novartis) (F)(PFL) no preservative1 mL SWI1,2 direct diluent against side of vial during reconstitution1 do NOT shake1 18 million unit/mL ( mg/mL)1,2 48 h F1 50 mL D5W1 30 70 mcg/mL1 Less than 30 mcg/mL: dilute in D5W containing human albumin 48 h F1 - do not use in-line filter1,2 - avoid bacteriostatic water for injection or NS due to increased aggregation1 SC syringe3,4 14 d F4 **(PFL) Alemtuzumab 30 mg/mL (Genzyme/Bayer)5 (F)(PFL) do not shake no preservative6 N/A filter NOT required6 30 mg/mL6 discard unused portion6 SC syringe7 disc
Product Product Stability Special Precautions/Notes BCG (Tice substrain) intravesical 50 mg = 1 to 8 x 108 CFU (Merck Canada) (F)(PFL) no preservative25 1 mL preservative-free NS25 allow to stand for a few minutes, then gently swirl to suspend25 record time of reconstitution 1 to 8×108 CFU/vial25 2 h F25 **(PFL)25 transfer from vial to
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: